Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Proshares Trust (ZBIO) Accounts Payables (2023 - 2025)

Historic Accounts Payables for Zenas BioPharma (ZBIO) over the last 3 years, with Q3 2025 value amounting to $6.4 million.

  • Zenas BioPharma's Accounts Payables fell 5727.36% to $6.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.4 million, marking a year-over-year decrease of 5727.36%. This contributed to the annual value of $17.1 million for FY2024, which is 21756.86% up from last year.
  • Per Zenas BioPharma's latest filing, its Accounts Payables stood at $6.4 million for Q3 2025, which was down 5727.36% from $7.9 million recorded in Q2 2025.
  • In the past 5 years, Zenas BioPharma's Accounts Payables registered a high of $20.0 million during Q1 2025, and its lowest value of $5.4 million during Q4 2023.
  • Moreover, its 3-year median value for Accounts Payables was $11.5 million (2024), whereas its average is $12.0 million.
  • Its Accounts Payables has fluctuated over the past 5 years, first soared by 21756.86% in 2024, then plummeted by 5727.36% in 2025.
  • Quarter analysis of 3 years shows Zenas BioPharma's Accounts Payables stood at $5.4 million in 2023, then surged by 217.57% to $17.1 million in 2024, then tumbled by 62.39% to $6.4 million in 2025.
  • Its last three reported values are $6.4 million in Q3 2025, $7.9 million for Q2 2025, and $20.0 million during Q1 2025.